Mariusz Kowalewski MD, PhD , Michał Święczkowski MD , Łukasz Kuźma MD, PhD , Bart Maesen MD, PhD , Emil Julian Dąbrowski MD , Matteo Matteucci MD , Jakub Batko MD, PhD , Radosław Litwinowicz MD, PhD , Adam Kowalówka MD, PhD , Wojciech Wańha MD, PhD , Federica Jiritano MD, PhD , Giuseppe Maria Raffa MD, PhD , Pietro Giorgio Malvindi MD, PhD , Luigi Pannone MD , Paolo Meani MD, PhD , Roberto Lorusso MD, PhD , Richard Whitlock MD, PhD , Mark La Meir MD, PhD , Carlo de Asmundis MD, PhD , James Cox MD, PhD , Piotr Suwalski MD, PhD
{"title":"Systematic review and meta-analysis of left atrial appendage closure's influence on early and long-term mortality and stroke","authors":"Mariusz Kowalewski MD, PhD , Michał Święczkowski MD , Łukasz Kuźma MD, PhD , Bart Maesen MD, PhD , Emil Julian Dąbrowski MD , Matteo Matteucci MD , Jakub Batko MD, PhD , Radosław Litwinowicz MD, PhD , Adam Kowalówka MD, PhD , Wojciech Wańha MD, PhD , Federica Jiritano MD, PhD , Giuseppe Maria Raffa MD, PhD , Pietro Giorgio Malvindi MD, PhD , Luigi Pannone MD , Paolo Meani MD, PhD , Roberto Lorusso MD, PhD , Richard Whitlock MD, PhD , Mark La Meir MD, PhD , Carlo de Asmundis MD, PhD , James Cox MD, PhD , Piotr Suwalski MD, PhD","doi":"10.1016/j.xjon.2024.02.022","DOIUrl":null,"url":null,"abstract":"<div><h3>Objective</h3><p>Left atrial appendage closure (LAAC) concomitant to heart surgery in patients with underlying atrial fibrillation (AF) has gained attention because of long-term reduction of thromboembolic complications. As of mortality benefits in the setting of non-AF, data from both observational studies and randomized controlled trials are conflicting.</p></div><div><h3>Methods</h3><p>On-line databases were screened for studies comparing LAAC versus no LAAC concomitant to other heart surgery. End points assessed were all-cause mortality and stroke at early and longest-available follow-up. Subgroup analyses stratified on preoperative AF were performed. Risk ratios (RR) with 95% CIs served as primary statistics.</p></div><div><h3>Results</h3><p>Electronic search yielded 25 studies (N = 660 [158 patients]). There was no difference between LAAC and no LAAC in terms of early mortality. In the overall population analysis, LAAC reduced long-term mortality (RR, 0.86; 95% CI, 0.74-1.00; <em>P</em> = .05; <em>I</em><sup>2</sup> = 88%), reduced early stroke risk by 19% (RR, 0.81; 95% CI, 0.72-0.93; <em>P</em> = .002; <em>I</em><sup>2</sup> = 57%), and reduced late stroke risk by 13% (RR, 0.87; 95% CI, 0.84-0.90; <em>P</em> < .001; <em>I</em><sup>2</sup> = 58%). Subgroup analysis showed lower mortality (RR, 0.85; 95% CI, 0.72-1.01; <em>P</em> = .06; <em>I</em><sup>2</sup> = 91%), short-, and long-term stroke risk reduction only in patients with preoperative AF (RR, 0.81; 95% CI, 0.71-0.93; <em>P</em> = .003; <em>I</em><sup>2</sup> = 71% and RR, 0.87; 95% CI, 0.84-0.91; <em>P</em> < .001; <em>I</em><sup>2</sup> = 70%, respectively). No benefit of LAAC in patients without AF was found.</p></div><div><h3>Conclusions</h3><p>Concomitant LAAC was associated with reduced stroke rates at early and long-term and possibly reduced all-cause mortality at the long-term follow-up but the benefits were limited to patients with preoperative AF. There is not enough evidence to support routine concomitant LAAC in non-AF settings.</p></div>","PeriodicalId":74032,"journal":{"name":"JTCVS open","volume":"19 ","pages":"Pages 131-163"},"PeriodicalIF":0.0000,"publicationDate":"2024-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2666273624000585/pdfft?md5=c21d11a31c91a61dd45c5196fcb5b057&pid=1-s2.0-S2666273624000585-main.pdf","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"JTCVS open","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2666273624000585","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
Abstract
Objective
Left atrial appendage closure (LAAC) concomitant to heart surgery in patients with underlying atrial fibrillation (AF) has gained attention because of long-term reduction of thromboembolic complications. As of mortality benefits in the setting of non-AF, data from both observational studies and randomized controlled trials are conflicting.
Methods
On-line databases were screened for studies comparing LAAC versus no LAAC concomitant to other heart surgery. End points assessed were all-cause mortality and stroke at early and longest-available follow-up. Subgroup analyses stratified on preoperative AF were performed. Risk ratios (RR) with 95% CIs served as primary statistics.
Results
Electronic search yielded 25 studies (N = 660 [158 patients]). There was no difference between LAAC and no LAAC in terms of early mortality. In the overall population analysis, LAAC reduced long-term mortality (RR, 0.86; 95% CI, 0.74-1.00; P = .05; I2 = 88%), reduced early stroke risk by 19% (RR, 0.81; 95% CI, 0.72-0.93; P = .002; I2 = 57%), and reduced late stroke risk by 13% (RR, 0.87; 95% CI, 0.84-0.90; P < .001; I2 = 58%). Subgroup analysis showed lower mortality (RR, 0.85; 95% CI, 0.72-1.01; P = .06; I2 = 91%), short-, and long-term stroke risk reduction only in patients with preoperative AF (RR, 0.81; 95% CI, 0.71-0.93; P = .003; I2 = 71% and RR, 0.87; 95% CI, 0.84-0.91; P < .001; I2 = 70%, respectively). No benefit of LAAC in patients without AF was found.
Conclusions
Concomitant LAAC was associated with reduced stroke rates at early and long-term and possibly reduced all-cause mortality at the long-term follow-up but the benefits were limited to patients with preoperative AF. There is not enough evidence to support routine concomitant LAAC in non-AF settings.